FI981954A - Parannettu näkökyky silmän fotodynaamisen terapian avulla - Google Patents

Parannettu näkökyky silmän fotodynaamisen terapian avulla Download PDF

Info

Publication number
FI981954A
FI981954A FI981954A FI981954A FI981954A FI 981954 A FI981954 A FI 981954A FI 981954 A FI981954 A FI 981954A FI 981954 A FI981954 A FI 981954A FI 981954 A FI981954 A FI 981954A
Authority
FI
Finland
Prior art keywords
eye
photodynamic therapy
improved vision
vision
improved
Prior art date
Application number
FI981954A
Other languages
English (en)
Swedish (sv)
Other versions
FI981954A0 (fi
Inventor
H Andrew Strong
Julia Levy
Gustav Huber
Mario Fsadni
Original Assignee
Qlt Phototherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlt Phototherapeutics Inc filed Critical Qlt Phototherapeutics Inc
Publication of FI981954A0 publication Critical patent/FI981954A0/fi
Publication of FI981954A publication Critical patent/FI981954A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
FI981954A 1996-03-11 1998-09-11 Parannettu näkökyky silmän fotodynaamisen terapian avulla FI981954A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/613,420 US5756541A (en) 1996-03-11 1996-03-11 Vision through photodynamic therapy of the eye
PCT/CA1997/000134 WO1997033619A1 (en) 1996-03-11 1997-02-25 Improved vision through photodynamic therapy of the eye

Publications (2)

Publication Number Publication Date
FI981954A0 FI981954A0 (fi) 1998-09-11
FI981954A true FI981954A (fi) 1998-11-10

Family

ID=24457246

Family Applications (1)

Application Number Title Priority Date Filing Date
FI981954A FI981954A (fi) 1996-03-11 1998-09-11 Parannettu näkökyky silmän fotodynaamisen terapian avulla

Country Status (22)

Country Link
US (6) US5756541A (fi)
EP (1) EP0894009B1 (fi)
JP (2) JP2000506173A (fi)
KR (1) KR100433507B1 (fi)
CN (1) CN1104908C (fi)
AR (2) AR004422A1 (fi)
AT (1) ATE301473T1 (fi)
CA (1) CA2248087C (fi)
CZ (1) CZ299301B6 (fi)
DE (1) DE69733943T2 (fi)
DK (1) DK0894009T3 (fi)
ES (1) ES2246505T3 (fi)
FI (1) FI981954A (fi)
HK (1) HK1018203A1 (fi)
HU (1) HU227978B1 (fi)
IL (4) IL126099A (fi)
NO (1) NO984163L (fi)
NZ (1) NZ331736A (fi)
PL (1) PL188888B1 (fi)
TW (1) TW448045B (fi)
WO (1) WO1997033619A1 (fi)
ZA (1) ZA971820B (fi)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130246A0 (en) * 1996-12-11 2000-06-01 Pharmacyclics Inc Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
EP0996465B1 (en) * 1997-02-11 2004-06-30 QLT Inc. Compositions and articles for reducing the effects of inflammation
US6117862A (en) 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US6443976B1 (en) * 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US7078014B2 (en) * 1999-12-23 2006-07-18 Health Research, Inc. Method for using chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US6534040B2 (en) 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US7097826B2 (en) 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US20020049247A1 (en) * 2000-01-12 2002-04-25 Chen James C. Novel treatment for eye disease
AU2001234979B2 (en) 2000-02-10 2006-07-27 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
AU2006203034B2 (en) * 2000-02-10 2006-09-07 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
PL359027A1 (en) * 2000-03-24 2004-08-23 Novartis Ag Improved treatment of neovascularization
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
CA2437557C (en) * 2001-02-06 2012-07-24 Qlt Inc. Reduced total fluence photodynamic therapy of choroidal neovasculature in amd
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
AU2002233092A1 (en) 2001-02-15 2002-08-28 Qlt Inc. Reduction or prevention of pdt related inflammation
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US6599891B2 (en) * 2001-07-20 2003-07-29 Qlt Inc. Treatment of macular edema
IL161327A0 (en) * 2001-11-09 2004-09-27 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
US20030167033A1 (en) * 2002-01-23 2003-09-04 James Chen Systems and methods for photodynamic therapy
DE60332564D1 (de) * 2002-03-20 2010-06-24 Novadaq Technologies Inc System und Verfahren zur Ansicht des Flüssigkeitsstroms durch Gefäße
CN1678342A (zh) * 2002-07-02 2005-10-05 加州大学评议会 眼病症治疗
US7364574B2 (en) * 2002-07-17 2008-04-29 Novadaq Technologies Inc. Combined photocoagulation and photodynamic therapy
CA2500877A1 (en) * 2002-10-03 2004-04-15 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
WO2004034889A2 (en) * 2002-10-18 2004-04-29 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization
US20060141470A1 (en) * 2003-02-14 2006-06-29 Kalayoglu Murat V Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
EP1605847B1 (en) * 2003-03-07 2009-09-16 Board Of Regents, The University Of Texas System Antibody-targeted photodynamic therapy
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
MXPA05012165A (es) * 2003-05-14 2006-05-19 Univ Sherbrooke Porfirazinas amfifilicas trisulfonadas para aplicaciones fotodinamicas en medicina.
CN100534428C (zh) * 2003-08-25 2009-09-02 上海复旦张江生物医药股份有限公司 血卟啉单甲醚在治疗眼科疾病中的应用
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
JP2007536272A (ja) * 2004-05-07 2007-12-13 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 近視の処置法
US20060052286A1 (en) * 2004-08-13 2006-03-09 Yale University Factor VII conjugates for selectively treating neovascularization disorders
JP2008510529A (ja) * 2004-08-27 2008-04-10 エレックス メディカル プロプライエタリー リミテッド 選択的眼科レーザ治療
TW200610555A (en) * 2004-09-24 2006-04-01 Light Sciences Corp Extended treatment of tumors through vessel occlusion with light activated drugs
EP2186518A1 (en) * 2004-11-17 2010-05-19 McLaurin, Joanne Composition and methods for treatment of disorders of protein aggregation
US20060229284A1 (en) * 2004-12-15 2006-10-12 Mahoney Paula A Enhanced occlusive effect photodynamic therapy
WO2006091666A2 (en) * 2005-02-23 2006-08-31 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US20070122344A1 (en) 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
US20070111970A1 (en) * 2005-10-13 2007-05-17 Antonio Cruz Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence
US8658633B2 (en) * 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US20070248646A1 (en) * 2006-02-16 2007-10-25 Ali Hafezi-Moghadam Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
WO2007129221A2 (en) * 2006-02-17 2007-11-15 Waratah Parmaceuticals Inc Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
US20100113613A1 (en) * 2006-03-09 2010-05-06 Waratah Pharmaceuticals cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
US20110028719A1 (en) * 2006-05-19 2011-02-03 Jacek Slon-Usakiewicz Screening methods for amyloid beta modulators
US20080161744A1 (en) 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
JP2010507412A (ja) 2006-10-25 2010-03-11 エレックス アールアンドディー プロプライエタリー リミテッド 網膜再生
JP2010510254A (ja) * 2006-11-24 2010-04-02 ワラタ ファーマシューティカルズ， インコーポレイテッド アルツハイマー病および関連の神経変性疾患のための併用処置
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
US20110105626A1 (en) * 2007-04-12 2011-05-05 Mclaurin Joanne Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
EP2656839A1 (en) * 2007-04-12 2013-10-30 Waratah Pharmaceuticals, Inc. Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases
US20100144891A1 (en) * 2007-04-12 2010-06-10 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
US20100331267A1 (en) * 2007-04-12 2010-12-30 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies
CA2688564C (en) * 2007-05-30 2015-02-03 Ellex R & D Pty Ltd Retinal rejuvenation laser
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
WO2009126894A2 (en) * 2008-04-11 2009-10-15 Massachusetts Eye And Ear Infirmary Methods and compositions for the diagnosis and treatment of angiogenic disorders
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
EP2285421B1 (en) 2008-05-02 2018-04-11 Novadaq Technologies ULC Methods for production and use of substance-loaded erythrocytes for observation and treatment of microvascular hemodynamics
EP2349233A4 (en) * 2008-10-09 2012-04-18 Waratah Pharmaceuticals Inc USE OF SCYLLO-INOSITOLS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH MACULAR DEGENERATION
KR101018785B1 (ko) * 2008-11-28 2011-03-03 삼성전기주식회사 전자기 밴드갭 구조물 및 회로 기판
JP5781501B2 (ja) 2009-04-22 2015-09-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 改変されたＦｃＲｎ結合部位を有する抗体融合タンパク質
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US20140004510A1 (en) 2010-09-24 2014-01-02 Massachusetts Eye And Ear Infirmary Methods and compositions for prognosing and/or detecting age-related macular degeneration
JP6215203B2 (ja) * 2011-08-23 2017-10-18 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ． Ｌｔｄ 眼疾患および障害の治療用の（バクテリオ）クロロフィル光増感剤
US9211214B2 (en) 2012-03-21 2015-12-15 Valeant Pharmaceuticals International, Inc Photodynamic therapy laser
JP6028096B2 (ja) 2012-06-21 2016-11-16 ノバダック テクノロジーズ インコーポレイテッド 血管造影及びかん流の定量化並びに解析手法
US9962251B2 (en) 2013-10-17 2018-05-08 Boston Scientific Scimed, Inc. Devices and methods for delivering implants
CN107209118B (zh) 2014-09-29 2021-05-28 史赛克欧洲运营有限公司 在自体荧光存在下生物材料中目标荧光团的成像
CA2963450A1 (en) 2014-10-09 2016-04-14 Novadaq Technologies Inc. Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
KR20220120711A (ko) 2016-05-26 2022-08-30 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 폐혈관 질환 치료용 조성물 및 방법
WO2018145193A1 (en) 2017-02-10 2018-08-16 Novadaq Technologies ULC Open-field handheld fluorescence imaging systems and methods
KR20190056758A (ko) 2017-11-17 2019-05-27 주식회사 지뉴브 종양줄기세포 특성의 암을 치료하기 위한 항암 병용 요법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179120A (en) 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
US5776966A (en) 1992-05-27 1998-07-07 University Of British Columbia Selective cell inactivation in blood
CA2185644C (en) * 1994-03-14 2011-04-12 Joan W. Miller Use of green porphyrins in ocular diagnosis and therapy
JP2961074B2 (ja) * 1995-09-06 1999-10-12 明治製菓株式会社 光化学療法用の新生血管閉塞剤

Also Published As

Publication number Publication date
IL126099A0 (en) 1999-05-09
US20120310144A1 (en) 2012-12-06
US20030149012A1 (en) 2003-08-07
JP2006273853A (ja) 2006-10-12
CN1213314A (zh) 1999-04-07
EP0894009A1 (en) 1999-02-03
JP2000506173A (ja) 2000-05-23
US20080058403A1 (en) 2008-03-06
HUP9902012A3 (en) 2000-04-28
CA2248087A1 (en) 1997-09-18
CZ299301B6 (cs) 2008-06-11
IL187758A0 (en) 2008-03-20
PL328796A1 (en) 1999-02-15
DK0894009T3 (da) 2005-10-31
DE69733943D1 (de) 2005-09-15
NO984163D0 (no) 1998-09-10
NO984163L (no) 1998-11-11
HUP9902012A2 (hu) 1999-12-28
US8239978B2 (en) 2012-08-14
KR100433507B1 (ko) 2004-12-23
CN1104908C (zh) 2003-04-09
ZA971820B (en) 1997-10-10
CZ278998A3 (cs) 1999-05-12
US6548542B1 (en) 2003-04-15
NZ331736A (en) 2000-06-23
US5756541A (en) 1998-05-26
WO1997033619A1 (en) 1997-09-18
ES2246505T3 (es) 2006-02-16
KR19990087682A (ko) 1999-12-27
HK1018203A1 (en) 1999-12-17
AU705100B2 (en) 1999-05-13
PL188888B1 (pl) 2005-05-31
CA2248087C (en) 2007-10-16
TW448045B (en) 2001-08-01
IL126099A (en) 2012-08-30
DE69733943T2 (de) 2006-06-01
US5910510A (en) 1999-06-08
AR004422A1 (es) 1998-12-16
ATE301473T1 (de) 2005-08-15
IL220210A0 (en) 2012-07-31
FI981954A0 (fi) 1998-09-11
EP0894009B1 (en) 2005-08-10
AR042931A2 (es) 2005-07-06
IL220143A0 (en) 2012-07-31
AU1762697A (en) 1997-10-01
HU227978B1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
FI981954A (fi) Parannettu näkökyky silmän fotodynaamisen terapian avulla
CA2155833A1 (en) Photodynamic treatment of synovium
AU1302699A (en) Photodynamic therapy method and apparatus
AR037307A1 (es) Metodos para el tratamiento de enfermedades oculares neovasculares
WO2002096366A3 (en) Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
EP0726083A3 (en) Method and apparatus for the diagnostic and composite pulsed heating and photodynamic therapy treatment
WO2002069825A3 (en) Apparatus and method for photocosmetic and photodermatological treatment
HU9303320D0 (en) Method for developing sight lens and sight repairing lens
CA2134479A1 (en) Laser treatment
WO2007146101A3 (en) Continuous low irradiance photodynamic therapy system and method
IL122382A0 (en) Ultra-long flashlamp-excited pulse dye laser for therapy and method therefor
WO2002038078A3 (en) A method and apparatus for the correction of presbyopia using high intensity focused ultrasound
WO2003047682A3 (en) Phototherapy for psoriasis and other skin disorders
AR021061A1 (es) Metodo para producir imagenes y terapia fotodinamica mejoradas
NZ336196A (en) Use of green porphyrins for the treatment of secondary cataracts
AU1403399A (en) Method of treatment of pigmented cancer cells utilizing photodynamic therapy
AU5327696A (en) Device for the photodynamic treatment of living beings and of the organs thereof
CA2112444A1 (en) Medical Laser Apparatus and Diagnosing/Curing Apparatus Using the Medical Laser Apparatus
WO2000062701A3 (en) Method and apparatus for treating dental caries
EP0313901A3 (en) System for in vivo treatment of tumorous tissues on body surfaces
WO2002053224A3 (fr) Procede et dispositif de photo-surveillance complexe du poids corporel
JPH04338474A (ja) 医療用レーザ装置
WO2005105211A3 (en) Fractionized light pdt therapy for posterior eye disease
RU97116656A (ru) Способ лечения цистита
RU97113539A (ru) Способ лечения заболеваний, вызываемых микроорганизмами